Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eisai CoFRA:EII +2.57%67 EV-to-OCF is 21.02 as of Aug. 09, 2026, which is 175% above its 10-year median of 7.65. GuruFocus rates FRA:EII with a GF Score™ of 67/100 and a GF Value™ of €30.65 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Eisai Co ranks worse than 70.18% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Eisai Co's Enterprise Value is €7,197 Mil.
Eisai Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €342 Mil. Therefore, Eisai Co's EV-to-OCF for today is 21.02.
The historical rank and industry rank for Eisai Co's EV-to-OCF or its related term are showing as below:
FRA:EII'
s EV-to-OCF Range Over the Past 10 Years
Min: -1646.78 Med: 7.65 Max: 386.48
Current: 21.43
During the past 13 years, the highest EV-to-OCF of Eisai Co was 386.48. The lowest was -1646.78. And the median was 7.65.
FRA:EII's EV-to-OCF is ranked worse than 70.18% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.06
vs FRA:EII: 21.43
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eisai Co's share price for today is €25.97.
Eisai Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.787.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Eisai Co EV-to-OCF Related Terms
Eisai Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Eisai Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Eisai Co's EV-to-OCF falls into.
Eisai Co's current Enterprise Value is €7,197 Mil.
Eisai Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €342 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (FRA:EII) has a EV-to-OCF of 21.02 as of Aug. 09, 2026. This is 175% above median its historical median of 7.65. According to the industry distribution chart, Eisai Co ranks #706 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 70.2%.
Is Eisai Co's EV-to-OCF too high?
Eisai Co's current EV-to-OCF of 21.02 is 175% above median its 10-year median of 7.65. The Drug Manufacturers industry median EV-to-OCF is 11.06. Eisai Co's value of 21.02 is 90.1% above this industry median. Based on the distribution chart, Eisai Co ranks #706 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #706 out of 1006 companies for EV-to-OCF. This places Eisai Co in the lower half of its industry. The industry median EV-to-OCF is 11.06. Eisai Co's value of 21.02 is 90.1% above this benchmark. While the company's 10-year median is 7.65 vs. the industry median of 11.06, Eisai Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.06, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current EV-to-OCF of 21.02 is 90.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current EV-to-OCF is 21.02, which is 175% above median its own 10-year median of 7.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (FRA:EII) is currently considered Modestly Undervalued. The stock's GF Value™ is €30.65, compared to a current price of €25.97 — trading 15.3% below its estimated fair value. The current EV-to-OCF is 21.02, which is 175% above median its 10-year median of 7.65 and 90.1% above the Drug Manufacturers industry median of 11.06. Eisai Co's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Eisai Co (FRA:EII), the current EV-to-OCF is 21.02 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (FRA:EII) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of €25.97 is trading 15.3% below its estimated GF Value™ of €30.65.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for FRA:EII:
EV-to-OCF: 21.02 (175% above median its 10-year median of 7.65)
GF Value™: €30.65 vs. price of €25.97 (15.3% below fair value)
Industry Position: 90.1% above the Drug Manufacturers median (#706 of 1006)
No single metric tells the full story. See the FRA:EII stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
67GF Score
Get the complete analysis for FRA:EII
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EII has been successfully added to your 
